, Tracking Stock Market Picks
Enter Symbol:
Panacos Pharmaceuticals, Inc. (PANC) [hlAlert]

down 99.93 %

Panacos Pharmaceuticals, Inc. (PANC) rated Buy with price target $3 by Punk Ziegel & Co

Posted on: Thursday,  Dec 27, 2007  12:25 PM ET by Punk Ziegel & Co

Punk Ziegel & Co rated Buy Panacos Pharmaceuticals, Inc. (OTCBB: PANC) on 12/27/2007, when the stock price was $0.82.
Since then, Panacos Pharmaceuticals, Inc. has lost 99.94% as of 08/07/2015's recent price of $0.00.
If you would have followed this Punk Ziegel & Co's recommendation on PANC, you would have lost 99.93% of your investment in 2780 days.

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

Our Research Department takes a fresh, critical approach to analyzing primary sources and developing proprietary research. Many individuals, institutions, portfolio managers and hedge fund managers, on all levels, have been neglected by brokerage firms ignoring the demands for unbiased research. Ladenburg Thalmann provides a superior branded in-depth research product geared only to action-oriented investment ideas. Ladenburg Thalmann’s proprietary equity research tries to uncover crucial information before the rest of the Street. Our analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. We will not shy away from large cap names as long as we can bring value to our clients through timely, differentiated ideas.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/27/2007 12:25 PM Buy
0.82 3.00
as of 8/27/2015
1 Week   
1 Month up  400.00 %
3 Months up  400.00 %
1 YTD down  -80.76 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy